Novavax is a biotechnology company based in Gaithersburg, Maryland, focused on developing recombinant vaccines, including its COVID-19 vaccines Nuvaxovid and other candidates. The company employs 1,543 people and utilizes advanced nanoparticle technology and its Matrix-M adjuvant to enhance immune responses.
NVAX has been in the news recently: Shares of Novavax fell by 2.8% following the nomination of Robert F. Kennedy Jr. by Donald Trump for the position of Health Secretary. This decline was part of a broader trend affecting vaccine manufacturers, including Pfizer and Moderna, amid concerns over Kennedy's vaccine skepticism.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
